Loading
A phase 3 trial of Linvoseltamab, Elotuzumab, Pomalidomide in multiple myeloma, run by Regeneron Pharmaceuticals, now recruiting.
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT05730036 by Regeneron Pharmaceuticals, with 410 participants planned, started 2023-09-18 and due to reach its primary completion in 2033-04-19. Interventions recorded: Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone. Conditions listed: Relapsed Refractory Multiple Myeloma (RRMM). No results are recorded here; the registry entry is the source.
Shares Elotuzumab, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Elotuzumab, Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Linvoseltamab, Regeneron, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific).
Shares Linvoseltamab, Regeneron, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific).
Shares Pomalidomide, Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.